目的 探討金天格膠囊聯(lián)合利塞膦酸鈉膠囊治療絕經(jīng)后骨質(zhì)疏松的臨床療效。方法 選取2015年12月—2016年12月焦作市第二人民醫(yī)院風(fēng)濕免疫科收治的絕經(jīng)后骨質(zhì)疏松患者151例作為研究對象，所有患者隨機分為對照組（75例）和治療組（76例）。對照組早餐前30 min直立位口服利塞膦酸鈉膠囊，1粒/次，1次/d。治療組在對照組基礎(chǔ)上口服金天格膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療6個月。觀察兩組的臨床療效，比較兩組的骨代謝指標(biāo)和骨密度。結(jié)果 治療后，對照組和治療組的總有效率分別為80.00%、96.05%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組Ⅰ型前膠原氨基端前肽（PINP）、骨鈣素（BGP）和β-膠原降解產(chǎn)物（β-CTx）水平均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組骨密度均明顯升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組骨密度明顯高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 金天格膠囊聯(lián)合利塞膦酸鈉膠囊治療絕經(jīng)后骨質(zhì)疏松具有較好的臨床療效，能改善患者體內(nèi)的骨代謝指標(biāo)，提高骨密度，安全性較好，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Jintiange Capsules combined with Risedronate Sodium Capsules in treatment of postmenopausal osteoporosis. Methods Patients (151 cases) with postmenopausal osteoporosis in Department of Rheumatology of Jiaozuo Second People's Hospital from December 2015 to December 2016 were randomly divided into the control group (75 cases) and the treatment group (76 cases). Patients in the control group were po administered with Risedronate Sodium Capsules at 30 minutes before the meal, 1 grain/time, once daily. Patients in the treatment group were po administered with Jintiange Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and bone metabolism indexes and bone mineral density in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 96.05%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of PINP, BGP, and β-CTx in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the bone mineral densities in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the bone mineral density in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Jintiange Capsules combined with Risedronate Sodium Capsules has clinical curative effect in treatment of postmenopausal osteoporosis, can improve bone metabolism indexes, and increase the bone mineral density, with good safety, which has a certain clinical application value.